RT Journal Article
SR Electronic
T1 Medication-related adverse events in patients with cancer and discrepancies in cystatin C- versus creatinine-based eGFR
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.18.23284656
DO 10.1101/2023.01.18.23284656
A1 Hanna, Paul E.
A1 Wang, Qiyu
A1 Strohbehn, Ian
A1 Moreno, Daiana
A1 Harden, Destiny
A1 Ouyang, Tianqi
A1 Katz-Agranov, Nurit
A1 Seethapathy, Harish
A1 Reynolds, Kerry L.
A1 Gupta, Shruti
A1 Leaf, David E.
A1 Sise, Meghan E.
YR 2023
UL http://medrxiv.org/content/early/2023/01/18/2023.01.18.23284656.abstract
AB Background Creatinine-based estimated glomerular filtration rate (eGFRCRE) may overestimate kidney function in patients with cancer. Cystatin C-based eGFR (eGFRCYS) is an alternative marker of kidney function. We investigated whether patients with an eGFR discrepancy, defined as eGFRCYS >30% lower than the concurrent eGFRCRE, had an increased risk of adverse events resulting from renally-cleared medications.Patients and Methods We conducted a cohort study of adult patients with cancer who had serum creatinine and cystatin C measured on the same day between May 2010 and January 2022 at two academic cancer centers in Boston, MA. The primary outcome was the incidence of each of the following medication-related adverse events: 1) supratherapeutic vancomycin levels (>30μg/mL); 2) trimethoprim-sulfamethoxazole-related hyperkalemia (>5.5mEq/L); 3) baclofen-induced neurotoxicity; and 4) supratherapeutic digoxin levels (>2.0ng/mL).Results 1988 patients with cancer had simultaneous eGFRCYS and eGFRCRE. The mean age was 66 years (SD±14), 965 (49%) were female, and 1555 (78%) were non-Hispanic white. eGFR discrepancy occurred in 579 patients (29%). Patients with eGFR discrepancy were more likely to experience medication-related adverse events compared to those without eGFR discrepancy: vancomycin levels >30μg/mL (24% vs. 10%, p=0.004), trimethoprim-sulfamethoxazole-related hyperkalemia (24% vs. 12%, p=0.013), baclofen-induced neurotoxicity (25% vs. 0%, p=0.13), and supratherapeutic digoxin levels (38% vs. 0%, p=0.03). The adjusted OR for vancomycin levels >30μg/mL was 2.30 (95% CI 1.05 – 5.51, p = 0.047).Conclusion Among patients with cancer with simultaneous assessment of eGFRCYS and eGFRCRE, medication-related adverse events occur more commonly in those with eGFR discrepancy. These findings underscore the importance of accurate assessment of kidney function and appropriate dosing of renally-cleared medications in patients with cancer.Competing Interest StatementS. Gupta reports research support from BTG International and GE Healthcare. She is a member of GlaxoSmithKlines Global Anemia Council, a consultant for Secretome, and president and founder of the American Society of Onconephrology. MES: Reports research funding from Gilead, Merck, EMD Serono, and Angion. She has served as a scientific advisory board member to Mallinckrodt, Travere, and Novartis. DEL reports research support from BioPorto, BTG International, and Metro International Biotech LLC. All remaining authors have no conflict of interest.Funding StatementMES is funded by NIH grant R01DK130839 SG is funded by NIH grant K23DK125672 DEL is funded by NIH grants R01HL144566, R01DK125786, and R01DK126685Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study approved by the Massachusetts General Brigham Institutional Review BoardI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors